现代超大量输血后的结局:东部创伤外科协会多中心研究
该东部创伤外科协会多中心回顾性研究纳入17个创伤中心2014-2019年间461例24小时内接受≥20 U红细胞(UMT)的创伤患者,中位年龄35岁、ISS 33、休克指数1.2,中位输注RBC 29 U、FFP 22 U、PLT 24 U,24小时死亡率46%、出院死亡率65%。多因素分析显示RBC/FFP≥1.5:1或RBC/PLT≥1.5:1与死亡率显著相关,两者同时≥1.5:1者死亡风险更高(OR 3.11和2.81)。CART分析提示年龄>50岁、初始GCS低、血小板减少及复苏性开胸与低生存率(14-26%)相关,而无这些因素者生存率最高(71%)。
要点
- UMT定义为24小时内输注≥20 U浓缩红细胞;本研究中46%患者24小时死亡、65%出院死亡,资源消耗高且预后差。
- RBC/FFP≥1.5:1或RBC/PLT≥1.5:1与死亡率显著相关;两者同时≥1.5:1的18%患者24小时及出院死亡OR分别为3.11和2.81(均p<0.01)。
- 年龄>50岁、初始GCS低、血小板减少、复苏性开胸四项因素并存时生存率仅14-26%,四项均无时生存率最高达71%,可用于预后判断。
- 现代大量输血方案下仍有近半数UMT患者接受不平衡比例输血,提示床旁执行中需持续关注并维持平衡的血液制品比例。
适用人群与场景
- 来自17个创伤中心、2014-2019年间24小时内接受≥20 U浓缩红细胞的创伤患者,共461例;中位年龄35岁、82%为男性、中位ISS 33、中位休克指数1.2、碱剩余-9。
诊断标准与关键阈值
- UMT定义为24小时内输注≥20 U浓缩红细胞(packed red blood cells, RBC)。
- 不平衡输血比例定义为RBC/FFP≥1.5:1或RBC/PLT≥1.5:1。
- CART分析中与低生存率相关的因素:年龄>50岁、初始GCS低、血小板减少、复苏性开胸。
处置流程与药物剂量
- 原文未提及具体的药物剂量、给药途径、频次或目标值;仅强调在UMT期间维持平衡的RBC/FFP和RBC/PLT比例(避免≥1.5:1),但未给出具体比例目标或方案细节。
红旗征与不能漏的情况
- 年龄>50岁、初始GCS低、血小板减少、需复苏性开胸:这些因素与极低生存率(14-26%)相关,应尽早识别并用于预后判断。
- 接受UMT时出现RBC/FFP≥1.5:1或RBC/PLT≥1.5:1的不平衡输血比例,与24小时和出院死亡率增加独立相关。
研究设计与关键结果
- 研究类型:东部创伤外科协会(EAST)多中心回顾性研究,纳入17个创伤中心、461例接受UMT的创伤患者(2014-2019年)。
- 人群特征:中位年龄35岁、82%男性、中位ISS 33、中位休克指数1.2、碱剩余-9;中位输注RBC 29 U、FFP 22 U、PLT 24 U。
- 主要结局:24小时死亡率46%,出院死亡率65%。
- 关键结果:RBC/FFP≥1.5:1或RBC/PLT≥1.5:1与死亡率显著相关;两者同时≥1.5:1的18%患者24小时及出院死亡OR分别为3.11和2.81(均p<0.01)。
- CART分析:年龄>50岁、低初始GCS、血小板减少、复苏性开胸与低生存率(14-26%)相关;无这些因素者生存率最高(71%)。
证据类型、等级与局限
- 证据类型:多中心回顾性队列研究(EAST multicenter retrospective study),证据等级为预后性研究Level III。
- 局限:回顾性设计、观察性研究,无法确立因果关系;原文未提及其他局限。
对床旁实践的改变
- 在超大量输血(≥20 U RBC/24h)过程中应持续监测并维持RBC/FFP和RBC/PLT比例平衡,避免≥1.5:1的不平衡比例,因其与死亡率增加相关。
- 对年龄>50岁、初始GCS低、血小板减少或需复苏性开胸的UMT患者,可参考CART结果进行预后判断(生存率14-26%),但原文未提供基于这些因素的治疗调整建议。
- 原文未提及对具体输血方案(如比例目标、药物辅助)的改变推荐。
指南或共识出处
- Outcomes after ultramassive transfusion in the modern era: An Eastern Association for the Surgery of Trauma multicenter study. J Trauma Acute Care Surg.
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite the widespread institution of modern massive transfusion protocols with balanced blood product ratios, survival for patients with traumatic hemorrhage receiving ultramassive transfusion (UMT) (defined as ≥20 U of packed red blood cells [RBCs]) in 24 hours) remains low and resource consumption remains high. Therefore, we aimed to identify factors associated with mortality in trauma patients receiving UMT in the modern resuscitation era.
METHODS: An Eastern Association for the Surgery of Trauma multicenter retrospective study of 461 trauma patients from 17 trauma centers who received ≥20 U of RBCs in 24 hours was performed (2014-2019). Multivariable logistic regression and Classification and Regression Tree analysis were used to identify clinical characteristics associated with mortality.
RESULTS: The 461 patients were young (median age, 35 years), male (82%), severely injured (median Injury Severity Score, 33), in shock (median shock index, 1.2; base excess, -9), and transfused a median of 29 U of RBCs, 22 U of fresh frozen plasma (FFP), and 24 U of platelets (PLT). Mortality was 46% at 24 hours and 65% at discharge. Transfusion of RBC/FFP ≥1.5:1 or RBC/PLT ≥1.5:1 was significantly associated with mortality, most pronounced for the 18% of patients who received both RBC/PLT and RBC/FFP ≥1.5:1 (odds ratios, 3.11 and 2.81 for mortality at 24 hours and discharge; both p < 0.01). Classification and Regression Tree identified that age older than 50 years, low initial Glasgow Coma Scale, thrombocytopenia, and resuscitative thoracotomy were associated with low likelihood of survival (14-26%), while absence of these factors was associated with the highest survival (71%).
CONCLUSION: Despite modern massive transfusion protocols, one half of trauma patients receiving UMT are transfused with either RBC/FFP or RBC/PLT in unbalanced ratios ≥1.5:1, with increased associated mortality. Maintaining focus on balanced ratios during UMT is critical, and consideration of advanced age, poor initial mental status, thrombocytopenia, and resuscitative thoracotomy can aid in prognostication.
LEVEL OF EVIDENCE: Prognostic, level III.
参考来源
- Matthay ZA, Hellmann ZJ, Callcut RA, et al. Outcomes after ultramassive transfusion in the modern era: An Eastern Association for the Surgery of Trauma multicenter study. J Trauma Acute Care Surg. 2021. PMID: 34144557. doi:10.1097/TA.0000000000003121
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。